Last reviewed · How we verify
Carvedilol CR
Carvedilol CR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.
Carvedilol CR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.
At a glance
| Generic name | Carvedilol CR |
|---|---|
| Also known as | Coreg CR, oral carvedilol in esclating doses |
| Sponsor | University of Florida |
| Drug class | Non-selective beta-blocker with alpha-1 blocking activity |
| Target | Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, reducing sympathetic nervous system activity. This dual action decreases heart rate and contractility while also causing vasodilation, lowering blood pressure and improving cardiac efficiency in heart failure and hypertension. The CR (controlled-release) formulation provides sustained drug delivery for once-daily dosing.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Left ventricular dysfunction following myocardial infarction
- Angina pectoris
Common side effects
- Dizziness
- Fatigue
- Bradycardia
- Hypotension
- Hyperglycemia
- Erectile dysfunction
Key clinical trials
- Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. (PHASE4)
- A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure (PHASE3)
- Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril (PHASE3)
- Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells (EARLY_PHASE1)
- Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab (PHASE2)
- Mechanisms of Refractory Hypertension (Carvedilol) (NA)
- Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease (PHASE1, PHASE2)
- Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carvedilol CR CI brief — competitive landscape report
- Carvedilol CR updates RSS · CI watch RSS
- University of Florida portfolio CI